A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, Wallace E, Deegan P, Tøndel C, Feldt-Rasmussen U, Hughes D, Sakov A, Rocco R, Almon EB, Alon S, Chertkoff R, Warnock DG, Waldek S, Wilcox WR, Bernat JA.
Holida M, et al. Among authors: almon eb.
J Inherit Metab Dis. 2024 Oct 9. doi: 10.1002/jimd.12795. Online ahead of print.
J Inherit Metab Dis. 2024.
PMID: 39381863